AR094374A1 - Composiciones y métodos para el tratamiento de trastornos metabólicos - Google Patents
Composiciones y métodos para el tratamiento de trastornos metabólicosInfo
- Publication number
- AR094374A1 AR094374A1 ARP140100044A ARP140100044A AR094374A1 AR 094374 A1 AR094374 A1 AR 094374A1 AR P140100044 A ARP140100044 A AR P140100044A AR P140100044 A ARP140100044 A AR P140100044A AR 094374 A1 AR094374 A1 AR 094374A1
- Authority
- AR
- Argentina
- Prior art keywords
- biguanide
- release
- biguanide compound
- compounds
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title 1
- 229940123208 Biguanide Drugs 0.000 abstract 4
- -1 biguanide compound Chemical class 0.000 abstract 4
- 150000004283 biguanides Chemical class 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 229960004111 buformin Drugs 0.000 abstract 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composiciones y métodos para mejorar la farmacocinética y reducir el riesgo de eventos adversos resultantes de la administración de compuestos de biguanida, que comprenden administrar formulaciones de acción retardada de dichos compuestos cuya liberación incluye una fase de latencia. Reivindicación 1: Una composición farmacéutica de liberación demorada apropiada para administrar compuestos de biguanida, caracterizada porque comprende una forma de dosificación oral que tiene un núcleo que comprende una cantidad eficaz para el uso terapéutico de un compuesto de biguanida y un recubrimiento entérico que rodea el núcleo, que es útil para demorar la liberación del compuesto de biguanida después de la ingestión, una vez alcanzada la porción distal del intestino delgado, y para minimizar la liberación del compuesto de biguanida de la forma de dosificación oral, con una fase de demora de al menos aproximadamente diez minutos, después de tomar contacto con un pH de al menos aproximadamente 6,0. Reivindicación 18: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque el compuesto de biguanida se selecciona del grupo que consiste en la metformina, la fenformina, la buformina y la imeglimina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749307P | 2013-01-05 | 2013-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094374A1 true AR094374A1 (es) | 2015-07-29 |
Family
ID=50030486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100044A AR094374A1 (es) | 2013-01-05 | 2014-01-06 | Composiciones y métodos para el tratamiento de trastornos metabólicos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20140193498A1 (es) |
| EP (2) | EP4410380A3 (es) |
| JP (1) | JP6333855B2 (es) |
| KR (1) | KR102229492B1 (es) |
| CN (2) | CN105101956B (es) |
| AR (1) | AR094374A1 (es) |
| AU (1) | AU2014203942B2 (es) |
| CA (1) | CA2896864C (es) |
| CL (1) | CL2015001914A1 (es) |
| CU (1) | CU20150071A7 (es) |
| EA (1) | EA039530B1 (es) |
| HK (1) | HK1214966A1 (es) |
| IL (1) | IL239722B (es) |
| MX (2) | MX376822B (es) |
| NZ (1) | NZ709525A (es) |
| PH (1) | PH12015501520A1 (es) |
| SG (2) | SG11201505240QA (es) |
| WO (1) | WO2014107617A1 (es) |
| ZA (1) | ZA201504858B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| SI2661266T1 (sl) | 2011-01-07 | 2021-01-29 | Anji Pharma (Us) Llc | Terapije, na osnovi kemosenzoričnih receptorskih ligandov |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| BR112014016810A8 (pt) | 2012-01-06 | 2017-07-04 | Elcelyx Therapeutics Inc | composições e métodos para tratamento de distúrbios metabólicos |
| MX2014008190A (es) | 2012-01-06 | 2015-02-04 | Elcelyx Therapeutics Inc | Composiciones de biguanida y métodos para tratar transtornos metabólicos. |
| US20180193274A1 (en) * | 2014-12-24 | 2018-07-12 | Principia Biopharma Inc. | Compositions for ileo-jejunal drug delivery |
| WO2016205754A1 (en) * | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
| WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
| WO2018132768A1 (en) * | 2017-01-13 | 2018-07-19 | Sanna Pietro P | Methods and compositions for treating hpa hyperactivity |
| FR3068601B1 (fr) * | 2017-07-05 | 2021-02-19 | Eric Joseph Marie Fulgence Janin | Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire |
| US20220354800A1 (en) * | 2019-06-03 | 2022-11-10 | R.P. Scherer Technologies, Llc | Delayed release softgel capsules |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US20230000820A1 (en) * | 2021-06-28 | 2023-01-05 | ImmunoMet Therapeutics, Inc. | Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof |
| CN119499228A (zh) | 2023-08-22 | 2025-02-25 | 雅研(天津)生物医药科技中心(有限合伙) | 盐酸二甲双胍肠溶制剂 |
| CN119499203A (zh) | 2023-08-22 | 2025-02-25 | 雅研(天津)生物医药科技中心(有限合伙) | 一种盐酸二甲双胍肠溶片 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1209253A (en) | 1913-01-09 | 1916-12-19 | Automatic Electric Co | Impulse-transmitting device. |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS58403B2 (ja) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | Ｌ− アスコルビンサンセイザイノ セイゾウホウ |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| FR2704146B1 (fr) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| KR100510614B1 (ko) | 1997-04-15 | 2005-08-30 | 씨에스아이알 | 식욕 억제 활성을 갖는 화합물의 제조를 위한 중간체 및이의 제조 방법 |
| US5891919A (en) | 1997-09-19 | 1999-04-06 | Burlington Bio-Medical & Scientific Corp. | Denatonium capsaicinate and methods of producing the same |
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| ITMI991316A1 (it) | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
| IL132313A0 (en) | 1999-10-11 | 2001-03-19 | Yeda Res & Dev | Leptin assay |
| US20110217394A1 (en) | 2000-12-05 | 2011-09-08 | Brett Justin West | Iridoid Based Formulations |
| BRPI0206432A2 (pt) * | 2001-01-12 | 2016-10-25 | Sun Pharmaceutical Ind Ltd | métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento |
| AU2002307217A1 (en) | 2001-03-28 | 2002-10-15 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
| US8030008B2 (en) | 2001-04-05 | 2011-10-04 | Senomyx, Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
| US6830759B2 (en) * | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| US20060019346A1 (en) | 2002-07-29 | 2006-01-26 | Senomyx, Inc. | Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands |
| US7214387B2 (en) * | 2002-08-02 | 2007-05-08 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| CN1413582A (zh) * | 2002-11-29 | 2003-04-30 | 贵州圣济堂制药有限公司 | 盐酸二甲双胍肠溶片及其制备方法 |
| EP1581555B1 (en) | 2002-12-18 | 2008-04-30 | Givaudan SA | Chimeric alpha q-gustducin g-proteins |
| DE10308504A1 (de) | 2003-02-26 | 2004-09-09 | Basf Ag | Enzymatische Herstellung von (Meth)acrylsäureestern |
| WO2005009351A2 (en) | 2003-07-17 | 2005-02-03 | Santé International, Inc. | Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics |
| KR20070053659A (ko) | 2004-04-20 | 2007-05-25 | 도이체스 인스티튜트 퓌어 에른에룬그스포슝 | 쓴맛 수용체의 작용제 및 그의 용도 |
| US20060024335A1 (en) | 2004-07-29 | 2006-02-02 | Roger Stier E | Oral compositions which mask the bitter taste of a bitter-tasting agent |
| EP1815015B1 (en) | 2004-11-18 | 2012-05-23 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts | Agonists of bitter taste receptors and uses thereof |
| US20060222709A1 (en) * | 2005-03-18 | 2006-10-05 | Agi Therapeutics Research Ltd. | Metformin methods and formulations for treating chronic constipation |
| WO2006118341A1 (ja) | 2005-04-28 | 2006-11-09 | Ajinomoto Co., Inc. | 新規ラクタム化合物 |
| US20060269617A1 (en) | 2005-05-26 | 2006-11-30 | Suracell, Inc. | Supplement compositions and method of use for enhancement of insulin sensitivity |
| CA2612561A1 (en) | 2005-06-22 | 2007-01-04 | Senomyx, Inc. | Identification of human t2r recepors that are activated by bitter molecules in coffee (chlorogenic lactones) and related assays for identifying human bitter taste modulators |
| BRPI0615410A2 (pt) * | 2005-08-30 | 2013-02-13 | Nicholas Piramal India Ltd | composiÇço farmacÊutica de liberaÇço prolongada de metformina e processo para produÇço da mesma |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| US20070104805A1 (en) | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
| JP2007215162A (ja) | 2006-01-11 | 2007-08-23 | Canon Inc | 情報処理装置及びその制御方法、プログラム、記憶媒体 |
| US20070207227A1 (en) | 2006-02-23 | 2007-09-06 | Conopco, Inc., D/B/A Unilever, A Corporation Of New York | Appetite suppressant compositions |
| WO2007116404A2 (en) | 2006-04-10 | 2007-10-18 | Bar-Ilan University | Cucurbitacin glucosides and use thereof in treating cancer |
| CA2551706A1 (en) | 2006-06-27 | 2007-12-27 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and bitter melon |
| CN100596277C (zh) | 2006-07-10 | 2010-03-31 | 博仲盛景医药技术（北京）有限公司 | 一种促进肠胃蠕动的药物组合物 |
| CN101505771A (zh) | 2006-08-17 | 2009-08-12 | 荷兰联合利华有限公司 | 含有甾体糖苷的hoodia植物萃取物的制造方法 |
| AP2009004773A0 (en) | 2006-08-24 | 2009-02-28 | Unilever Plc | Process for preparing a composition comprising steroidal glycosides |
| CN101522702A (zh) | 2006-09-05 | 2009-09-02 | 塞诺米克斯公司 | 人T2R受体hT2R50的新单体型及其在鉴定人苦味调节剂的测定法中的用途 |
| EP1975612A1 (en) | 2007-03-29 | 2008-10-01 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand | Agonists of bitter taste receptors and uses thereof |
| EP1975611A1 (en) | 2007-03-29 | 2008-10-01 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand | Agonists of bitter taste receptors and uses thereof |
| US20090042813A1 (en) | 2007-08-10 | 2009-02-12 | Sergey Michailovich Melnikov | Hoodia extract oil compositions comprising medium chain triglycerides |
| WO2009053980A2 (en) | 2007-10-24 | 2009-04-30 | Arava Hoodia Growers A. C. S. Ltd. | An improved appetite suppressant |
| CN101918014B (zh) | 2008-01-29 | 2012-06-20 | 中森制药株式会社 | 医药组合物 |
| WO2009140784A1 (en) | 2008-05-23 | 2009-11-26 | Givaudan Sa | Bitter alkaloid containing consumables comprising bitter blockers |
| US8546085B2 (en) | 2008-06-13 | 2013-10-01 | Givaudan Sa | Methods of identifying modulators of the bitter taste receptor TAS2R44 |
| WO2010024393A1 (ja) | 2008-08-29 | 2010-03-04 | サントリーホールディングス株式会社 | 新規エピガロカテキンガレート４量体、およびそれらを含む血管内皮機能改善剤 |
| US8557530B2 (en) | 2008-08-29 | 2013-10-15 | Givaudan Sa | Use of a TAS2R7 nucleic acid sequence to identify modulators |
| WO2010060198A1 (en) | 2008-11-26 | 2010-06-03 | West Central Envirotech Inc. | Composition and method for controlling insects |
| JP5597142B2 (ja) | 2009-01-03 | 2014-10-01 | 静岡県公立大学法人 | 硫酸化ｃ−配糖体及びその単離方法並びに合成方法 |
| US8709745B2 (en) | 2009-07-28 | 2014-04-29 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Methods for isolating ligands of the human bitter taste receptor TAS2R49 |
| EP2490695B1 (en) | 2009-10-21 | 2013-11-20 | Wisconsin Alumni Research Foundation | Method of preventing type 1 diabetes |
| EP2689805A1 (en) | 2009-12-04 | 2014-01-29 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
| EP2345646A1 (en) | 2010-01-14 | 2011-07-20 | InterMed Discovery GmbH | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
| US20110293753A1 (en) | 2010-05-28 | 2011-12-01 | Louis Bellafiore | Tocotrienol Compositions |
| GB201009873D0 (en) | 2010-06-14 | 2010-07-21 | Univ Leuven Kath | Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium |
| EP2397039A1 (en) | 2010-06-21 | 2011-12-21 | Abbott Laboratories | Compositions for delaying progression of diabetes using Salacia oblonga extract |
| CN101978956B (zh) * | 2010-10-13 | 2012-03-28 | 北京京丰制药有限公司 | 盐酸二甲双胍肠溶片及其制备方法 |
| SI2661266T1 (sl) * | 2011-01-07 | 2021-01-29 | Anji Pharma (Us) Llc | Terapije, na osnovi kemosenzoričnih receptorskih ligandov |
| BR112014016810A8 (pt) * | 2012-01-06 | 2017-07-04 | Elcelyx Therapeutics Inc | composições e métodos para tratamento de distúrbios metabólicos |
| CN103768071B (zh) * | 2012-10-23 | 2016-08-17 | 中国医药工业研究总院 | 一种治疗糖尿病的口服制剂 |
-
2014
- 2014-01-03 SG SG11201505240QA patent/SG11201505240QA/en unknown
- 2014-01-03 EP EP24184490.1A patent/EP4410380A3/en active Pending
- 2014-01-03 MX MX2015008625A patent/MX376822B/es active IP Right Grant
- 2014-01-03 US US14/147,449 patent/US20140193498A1/en not_active Abandoned
- 2014-01-03 CA CA2896864A patent/CA2896864C/en active Active
- 2014-01-03 NZ NZ709525A patent/NZ709525A/en unknown
- 2014-01-03 HK HK16103014.8A patent/HK1214966A1/zh unknown
- 2014-01-03 CN CN201480003932.XA patent/CN105101956B/zh active Active
- 2014-01-03 EA EA201591085A patent/EA039530B1/ru unknown
- 2014-01-03 AU AU2014203942A patent/AU2014203942B2/en active Active
- 2014-01-03 WO PCT/US2014/010240 patent/WO2014107617A1/en not_active Ceased
- 2014-01-03 SG SG10201705437SA patent/SG10201705437SA/en unknown
- 2014-01-03 EP EP14702108.3A patent/EP2941245B1/en active Active
- 2014-01-03 MX MX2020011594A patent/MX389344B/es unknown
- 2014-01-03 JP JP2015551792A patent/JP6333855B2/ja active Active
- 2014-01-03 KR KR1020157019855A patent/KR102229492B1/ko active Active
- 2014-01-03 CN CN201910033955.XA patent/CN110051638B/zh active Active
- 2014-01-06 AR ARP140100044A patent/AR094374A1/es not_active Application Discontinuation
-
2015
- 2015-06-30 IL IL239722A patent/IL239722B/en unknown
- 2015-07-03 PH PH12015501520A patent/PH12015501520A1/en unknown
- 2015-07-03 CL CL2015001914A patent/CL2015001914A1/es unknown
- 2015-07-06 ZA ZA2015/04858A patent/ZA201504858B/en unknown
- 2015-07-06 CU CUP2015000071A patent/CU20150071A7/es unknown
-
2019
- 2019-11-26 US US16/695,498 patent/US20200093750A1/en not_active Abandoned
-
2024
- 2024-05-20 US US18/668,709 patent/US20250000804A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| JP2015038135A5 (es) | ||
| AR091089A1 (es) | Metodos de tratamiento que utilizan un compuesto de biguanida en una formulacion de liberacion demorada | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| CO2019008053A2 (es) | Agente terapéutico para enfermedades del hígado | |
| MX2015014656A (es) | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| WO2015099838A3 (en) | Compositions and methods of treating ocular diseases | |
| BR112015019264A8 (pt) | cápsulas para o tratamento de helicobacter pylori e seu uso". | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| WO2012106058A3 (en) | Animal treatments | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| DOP2013000115A (es) | Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma | |
| AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor | |
| MX2013008992A (es) | Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion. | |
| RU2014146303A (ru) | Способ лечения угрей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |